BPC November 17 update

Odonate ODT -29% Share repurchase; Cassava SAVA -24% SEC probe

Price and Volume Movers

Odonate Therapeutics, Inc. (NASDAQ: ODT) announced that it will commence a share repurchase plan for up to 20 million shares to return capital to stockholders. This action is in connection with the decision to discontinue the development of tesetaxel. Shares closed down 29% at $2.33.

The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences, Inc. (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer’s drug simufilam. Shares closed down 23% at $47.07.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced the pricing of a public offering of shares and warrants at $13.75 per share and $13.74 per pre-funded warrant. Total proceeds are to be $100.3 million. Shares closed up 31% at $18.40.

Atea Pharmaceuticals (NASDAQ: AVIR) announced during after-hours yesterday that its strategic collaboration with Roche Holding AG (OTC: RHHBY) for the development of AT-527 to treat COVID-19 will be terminated February 10, 2022. Shares closed down 24% at $8.69.

IMV, Inc. (NASDAQ: IMV) shares traded up after coverage by TipRanks noting that a Wells Fargo analyst Nick Abbot believes that it is overweight with a $14 price target. The TipRank article gave an overview of the company and upcoming catalysts. Shares closed up 18% at $1.73.

Advancers

CompanyPriceChange
BFRI
Biofrontera Inc.
$7.90+2.68  +51.34%
NRXP
NRX Pharmaceuticals Inc.
$6.75+2.25  +50.00%
ADGI
Adagio Therapeutics Inc.
$25.12+6.39  +34.12%
ATNF
180 Life Sciences Corp.
$5.41+0.95  +21.30%
GOVX
GeoVax Labs Inc.
$4.69+0.81  +20.88%
MRNA
Moderna Inc.
$329.63+56.24  +20.57%
ICVX
Icosavax Inc.
$27.55+4.51  +19.57%
VALN
Valneva SE
$59.60+9.7  +19.44%
TYRA
Tyra Biosciences Inc.
$23.87+3.66  +18.11%
PTPI
Petros Pharmaceuticals Inc.
$2.09+0.26  +14.21%

Decliners

CompanyPriceChange
LGVN
Longeveron Inc.
$30.67-11.63  -27.49%
AMTI
Applied Molecular Transport Inc.
$16.33-2.66  -14.01%
NEXI
NexImmune Inc.
$7.94-1.06  -11.78%
IGMS
IGM Biosciences Inc.
$49.63-6.58  -11.71%
CRNX
Crinetics Pharmaceuticals Inc.
$24.40-3.08  -11.21%
AVRO
AVROBIO Inc.
$4.08-0.51  -11.11%
ELYM
Eliem Therapeutics Inc
$13.76-1.72  -11.11%
MRSN
Mersana Therapeutics Inc.
$6.95-0.82  -10.55%
MNOV
MediciNova Inc.
$3.22-0.35  -9.80%
TARS
Tarsus Pharmaceuticals Inc.
$25.00-2.7  -9.75%

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

ABEO – Abeona Therapeutics Inc.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

$0.73
-0.03  -4%
Phase 1/2 Phase 1/2 updated safety data released February 12, 2021. Phase 1/2 pivotal data due in 2022.
$74.4 million

ARWR – Arrowhead Pharmaceuticals Inc.
JNJ-75220795
Non-alcoholic steatohepatitis (NASH)

$72.02
-2.02  -3%
Phase 1 Phase 1 trial ongoing.
$7.5 billion

DRMA – Dermata Therapeutics Inc.
DMT310
Rosacea

$2.70
-0.11  -4%
Phase 2 Phase 2 trial initiated, noted November 17, 2021. Phase 2 top-line data due 2H 2022.
$22.5 million

ELOX – Eloxx Pharmaceuticals Inc.
ELX-02
Cystic fibrosis

$0.69
-0.06  -8%
Phase 3 Phase 3 clinical development has started. Phase 2 monotherapy dosing data(n=12) at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity, noted November 17, 2021.
$59.5 million

ELOX – Eloxx Pharmaceuticals Inc.
ELX-02 combination with ivacaftor
Cystic fibrosis

$0.69
-0.06  -8%
Phase 2 Phase 2 first patient dosed, noted November 17, 2021. Phase 2 top-line data expected by the end 1H 2022.
$59.5 million

EXAI – Exscientia Plc
EXS-617
Breast and Ovarian cancer

$19.84
-1.39  -7%
Phase 1 Phase 1 data due in 1H 2022.
$2.4 billion

EXAI – Exscientia Plc
EXS-21546
High adenosine signature cancers

$19.84
-1.39  -7%
Phase 1 Phase 1 data due 1H 2022.
$2.4 billion

GRPH – Graphite Bio Inc.
GPH101 - (CEDAR)
Sickle Cell Disease

$9.56
-0.49  -5%
Phase 1/2 Phase 1/2 trial first patient enrolled November 17, 2021, treatment to begin in 1H 2022. Initial data due by end of 2022.
$555.2 million

JAGX – Jaguar Health Inc.
Mytesi (crofelemer) - (HALT-D)
Cancer related diarrhea (CRD)

$1.38
-0.05  -4%
Phase 2 Phase 2 results to be presented at San Antonio Breast Cancer Symposium December 10, 2021. Abstract reported that the primary endpoint - the incidence of having diarrhea for two or more days - was not statistically different for the two groups since about 70% of patients had this outcome regardless of cycle or CID treatment group, noted November 19, 2021. Phase 3 trial ongoing.
$63.6 million

MRTX – Mirati Therapeutics Inc.
MRTX1719
MTAP-deleted cancers

$136.76
-4.44  -3%
Phase 1/2 IND submitted for Phase 1/2 trial November 17, 2021. Trial to be initiated in 1Q 2022.
$7.6 billion

RHHBY – Roche Holding AG ADR
SPK-8011
Hemophilia A

$48.41
+0.08  +0%
Phase 1/2 Phase 1/2 data reported that 16 of 18 study participants had sustained factor VIII (FVIII). The trial demonstrated a 91.5% reduction in annualized bleed rate (ABR) and a 96.4% reduction in annualized number of FVIII infusions, noted November 17, 2021.
$330.8 billion